文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

免疫抑制合并急性呼吸衰竭患者无创正压通气失败的预测因素

[Predictive factors for failure of non-invasive positive pressure ventilation in immunosuppressed patients with acute respiratory failure].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2018-01-01
一句话结论免疫抑制合并急性呼吸衰竭患者中,APACHEⅡ评分≥20、PaO2/FiO2<100 mmHg及需用儿茶酚胺是无创正压通气失败的独立预测因素。

该研究回顾性分析新疆医科大学第一附属医院呼吸重症监护室2012年1月至2017年8月收治的118例接受无创正压通气的免疫缺陷合并急性呼吸衰竭患者,按住院期间是否气管插管分为非插管组62例和插管组56例。无创正压通气非插管率为50.8%(60/118)。多因素Logistic回归显示APACHEⅡ评分≥20(OR=15.274,95%CI 2.175-107.252,P=0.006)、PaO2/FiO2<100 mmHg(OR=0.075,95%CI 0.014-0.408,P=0.003)及需用儿茶酚胺(OR=35.736,95%CI 6.974-183.124,P<0.001)为无创正压通气失败的独立危险因素。ROC曲线显示APACHEⅡ评分≥20预测失败的AUC为0.787,PaO2/FiO2<100 mmHg的AUC为0.757。

要点

  • 免疫抑制合并急性呼吸衰竭患者接受无创正压通气,非插管率为50.8%(60/118),且不依赖急性呼吸衰竭病因。
  • APACHEⅡ评分≥20是无创正压通气失败的独立危险因素(OR=15.274,95%CI 2.175-107.252,P=0.006),预测AUC为0.787。
  • PaO2/FiO2<100 mmHg是无创正压通气失败的独立危险因素(OR=0.075,95%CI 0.014-0.408,P=0.003),预测AUC为0.757。
  • 需用儿茶酚胺是无创正压通气失败最强的独立危险因素(OR=35.736,95%CI 6.974-183.124,P<0.001)。
  • 与未插管组相比,插管组体温、pH值显著升高,PaCO2显著降低,PaO2/FiO2<100 mmHg、APACHEⅡ评分≥20及需用儿茶酚胺的例数显著增多,病死率显著升高。

适用人群与场景

  • 新疆医科大学第一附属医院呼吸重症监护室2012年1月至2017年8月收治的118例接受无创正压通气的免疫缺陷合并急性呼吸衰竭患者,按住院期间是否气管插管分为非插管组62例和插管组56例。

红旗征与不能漏的情况

  • APACHEⅡ评分≥20、PaO2/FiO2<100 mmHg或需用儿茶酚胺的免疫抑制合并急性呼吸衰竭患者,无创正压通气失败风险高,插管组病死率显著高于非插管组。

研究设计与关键结果

  • 回顾性分析118例免疫缺陷合并急性呼吸衰竭接受无创正压通气的患者,非插管率为50.8%(60/118)。
  • 与未插管组相比,插管组体温、pH值显著升高,PaCO2显著降低,PaO2/FiO2<100 mmHg、APACHEⅡ评分≥20及需用儿茶酚胺的例数显著增多,病死率显著升高。
  • 多因素Logistic回归显示APACHEⅡ评分≥20(OR=15.274,95%CI 2.175-107.252,P=0.006)、PaO2/FiO2<100 mmHg(OR=0.075,95%CI 0.014-0.408,P=0.003)及需用儿茶酚胺(OR=35.736,95%CI 6.974-183.124,P<0.001)为无创正压通气失败的独立危险因素。
  • ROC曲线显示APACHEⅡ评分≥20预测无创正压通气失败的AUC为0.787,敏感度83.93%,特异度69.35%,阳性预测值71.21%,阴性预测值82.69%,阳性似然比2.74,阴性似然比0.23,约登指数0.53。
  • PaO2/FiO2<100 mmHg预测无创正压通气失败的AUC为0.757,敏感度80.65%,特异度66.07%,阳性预测值68.18%,阴性预测值78.85%,阳性似然比2.38,阴性似然比0.29,约登指数0.47。

证据类型、等级与局限

  • 证据类型:回顾性分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,APACHEⅡ评分≥20、PaO2/FiO2<100 mmHg及需用儿茶酚胺是免疫抑制合并急性呼吸衰竭患者无创正压通气失败的预测因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the predictive factors for failure of non-invasive positive pressure ventilation (NIPPV) in immunosuppressed patients with acute respiratory failure (ARF).

METHODS: The clinical data of 118 immuno-deficient patients treated with NIPPV in the respiratory and intensive care unit (RICU) of the First Affiliated Hospital of Xinjiang Medical University from January 2012 to August 2017 were retrospectively analyzed. The patients were divided into a non-endotracheal intubation (ETI) group (n = 62) and ETI group (n = 56) according to whether ETI was performed during the hospitalization period or not. Each observed indicator was analyzed by univariate analysis, and factors leading to failure of NIPPV were further analyzed by Logistic regression. Receiver operating characteristic (ROC) curve was plotted to evaluate the predictive value of risk factors for failure of NIPPV in immunosuppressed patients with ARF.

RESULTS: The non-intubation rate for NIPPV in immunosuppressed patients was 50.8% (60/118). Compared with the non-ETI group, the body temperature, pH value in the ETI group were significantly increased, the partial pressure of arterial carbon dioxide (PaCO2) was significantly decreased, the ratio of oxygenation index (PaO2/FiO2) < 100 mmHg (1 mmHg = 0.133 kPa), acute physiology and chronic health evaluation II (APACHE II) score ≥ 20, and the number of cases requiring catecholamine were significantly increased, the mortality was significantly increased. Multivariate Logistic regression analysis showed that the APACHE II score ≥ 20 [odds ratio (OR) = 15.274, 95% confidence internal (95%CI) = 2.175-107.252, χ2 = 7.516, P = 0.006], PaO2/FiO2 < 100 mmHg (OR = 0.075, 95%CI = 0.014-0.408, χ2 = 8.968, P = 0.003), and need for catecholamine (OR = 35.736, 95%CI = 6.974-183.124, χ2 = 18.400, P < 0.001) were independent risk factors for failure of NIPPV. ROC curve analysis showed that the APACHE II score ≥ 20 and PaO2/FiO2 < 100 mmHg could predict failure of NIPPV, the area under ROC curve (AUC) of the APACHE II score ≥ 20 was 0.787, the sensitivity was 83.93%, the specificity was 69.35%, the positive predict value (PPV) was 71.21%, the negative predict value (NPV) was 82.69%, the positive likelihood ratio (PLR) was 2.74, the negative likelihood ratio (NLR) was 0.23, and Youden index was 0.53; the AUC of PaO2/FiO2 < 100 mmHg was 0.757, the sensitivity was 80.65%, the specificity was 66.07%, the PPV was 68.18%, the NPV was 78.85%, the PLR was 2.38, the NLR was 0.29, and Youden index was 0.47.

CONCLUSIONS: 50.8% of immunocompromised and ARF patients treated with NIPPV did not require ETI, which is independent of the etiology of ARF. APACHE II score ≥ 20, PaO2/FiO2 < 100 mmHg, and the need for catecholamine are predictive factors for failure of NIPPV in immunocompromised patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Jia X, Yan C, Xu S, et al. [Predictive factors for failure of non-invasive positive pressure ventilation in immunosuppressed patients with acute respiratory failure]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 29402357. doi:10.3760/cma.j.issn.2095-4352.2018.02.003

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。